BACKGROUND: Mannose-binding lectin (MBL) activates the complement system promoting opsonophagocytosis, which could represent an advantage for Mycobacterium leprae, an intracellular pathogen. Therefore, a single nucleotide polymorphism (SNP) in the MBL2 gene associated with low levels of MBL could confer protection against the development of leprosy disease. METHODS: In this study, we investigated SNPs of the MBL2 gene and MBL levels in 228 Brazilian leprosy patients and 232 controls. RESULTS: There were no differences in the frequencies of variant genotypes and haplotypes of MBL2 between patients and controls, or between the different clinical forms of leprosy. In the group of patients with a genotype for high expression of MBL2, those aged>40 years had decreased MBL levels compared to patients aged ≤ 40 years (p = 0.037). CONCLUSION: Our results demonstrate that age could influence the phenotype of MBL2, but no evidence was found for an association of MBL2 polymorphism with susceptibility to leprosy or its clinical forms.
BACKGROUND:Mannose-binding lectin (MBL) activates the complement system promoting opsonophagocytosis, which could represent an advantage for Mycobacterium leprae, an intracellular pathogen. Therefore, a single nucleotide polymorphism (SNP) in the MBL2 gene associated with low levels of MBL could confer protection against the development of leprosy disease. METHODS: In this study, we investigated SNPs of the MBL2 gene and MBL levels in 228 Brazilian leprosypatients and 232 controls. RESULTS: There were no differences in the frequencies of variant genotypes and haplotypes of MBL2 between patients and controls, or between the different clinical forms of leprosy. In the group of patients with a genotype for high expression of MBL2, those aged>40 years had decreased MBL levels compared to patients aged ≤ 40 years (p = 0.037). CONCLUSION: Our results demonstrate that age could influence the phenotype of MBL2, but no evidence was found for an association of MBL2 polymorphism with susceptibility to leprosy or its clinical forms.
Authors: Priscila Saamara Mazini; Hugo Vicentin Alves; Pâmela Guimarães Reis; Ana Paula Lopes; Ana Maria Sell; Manuel Santos-Rosa; Jeane Eliete Laguila Visentainer; Paulo Rodrigues-Santos Journal: Front Immunol Date: 2016-01-12 Impact factor: 7.561
Authors: N Lucena-Silva; M A G Teixeira; A de L Ramos; R S de Albuquerque; G T N Diniz; C T Mendes-Junior; E C Castelli; E A Donadi Journal: Mol Genet Genomic Med Date: 2013-06-07 Impact factor: 2.183
Authors: Bruna Tiaki Tiyo; Evelyn Castillo Lima Vendramini; Victor Hugo de Souza; Cristiane Maria Colli; Hugo Vicentin Alves; Ana Maria Sell; Sylmara Bessani Paixão Zucoloto; Jeane Eliete Laguila Visentainer Journal: Front Immunol Date: 2020-09-03 Impact factor: 7.561